Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy

Si‐Man Huang; Chao‐Ling Wan; Han‐Yu Cao; Yan‐Yan Li; Chong‐Sheng Qian; Hai‐Xia Zhou; Ming‐Zhu Xu; Xiao‐Hui Hu; Lan Dai; Hai‐Ping Dai; Sheng‐Li Xue

doi:10.1002/ccr3.8289

Clinical Case Reports (Dec 2023)

Preemptive inotuzumab ozogamicin eradicated measurable residual disease in Ph‐negative acute lymphoblastic leukemia relapsed post CD19 CART therapy

Si‐Man Huang,
Chao‐Ling Wan,
Han‐Yu Cao,
Yan‐Yan Li,
Chong‐Sheng Qian,
Hai‐Xia Zhou,
Ming‐Zhu Xu,
Xiao‐Hui Hu,
Lan Dai,
Hai‐Ping Dai,
Sheng‐Li Xue

Affiliations

Si‐Man Huang: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Chao‐Ling Wan: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Han‐Yu Cao: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Yan‐Yan Li: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Chong‐Sheng Qian: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Hai‐Xia Zhou: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Ming‐Zhu Xu: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Xiao‐Hui Hu: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Lan Dai: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Hai‐Ping Dai: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China
Sheng‐Li Xue: National Clinical Research Center for Hematologic Diseases, Jiangsu Institute of Hematology The First Affiliated Hospital of Soochow University Suzhou China

DOI: https://doi.org/10.1002/ccr3.8289
Journal volume & issue: Vol. 11, no. 12
pp. n/a – n/a

Abstract

Read online

Key Clinical Message There are no reports of application of inotuzumab ozogamicin (InO) for the treatment of MRD in r/r B‐ALL. We firstly report the efficacy of InO for a patient experienced morphological relapse after HSCT and molecular relapse after CART therapy.

Published in Clinical Case Reports

ISSN: 2050-0904 (Online)
Publisher: Wiley
Country of publisher: United Kingdom
LCC subjects: Medicine: Medicine (General)
Website: http://onlinelibrary.wiley.com/journal/10.1002/(ISSN)2050-0904

About the journal

Abstract

Keywords